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Exome Sequencing Identifies Mitochondrial
Alanyl-tRNA Synthetase Mutations
in Infantile Mitochondrial Cardiomyopathy
Alexandra Go¨tz,1,13 Henna Tyynismaa,1,13 Liliya Euro,1 Pekka Ellonen,2 Tuulia Hyo¨tyla¨inen,3
Tiina Ojala,4 Riikka H. Ha¨ma¨la¨inen,1 Johanna Tommiska,5,6 Taneli Raivio,5,6 Matej Oresic,3
Riitta Karikoski,7,8 Outi Tammela,9 Kalle O.J. Simola,10 Anders Paetau,7,8 Tiina Tyni,1,11
and Anu Suomalainen1,2,12,*
Infantile cardiomyopathies are devastating fatal disorders of the neonatal period or the first year of life. Mitochondrial dysfunction is
a common cause of this group of diseases, but the underlying gene defects have been characterized in only a minority of cases, because
tissue specificity of the manifestation hampers functional cloning and the heterogeneity of causative factors hinders collection of
informative family materials. We sequenced the exome of a patient who died at the age of 10 months of hypertrophic mitochondrial
cardiomyopathy with combined cardiac respiratory chain complex I and IV deficiency. Rigorous data analysis allowed us to identify
a homozygous missense mutation in AARS2, which we showed to encode the mitochondrial alanyl-tRNA synthetase (mtAlaRS). Two
siblings from another family, both of whom died perinatally of hypertrophic cardiomyopathy, had the same mutation, compound
heterozygous with another missense mutation. Protein structure modeling of mtAlaRS suggested that one of the mutations affected
a unique tRNA recognition site in the editing domain, leading to incorrect tRNA aminoacylation, whereas the secondmutation severely
disturbed the catalytic function, preventing tRNA aminoacylation. We show here that mutations in AARS2 cause perinatal or infantile
cardiomyopathy with near-total combined mitochondrial respiratory chain deficiency in the heart. Our results indicate that exome
sequencing is a powerful tool for identifying mutations in single patients and allows recognition of the genetic background in single-
gene disorders of variable clinical manifestation and tissue-specific disease. Furthermore, we show that mitochondrial disorders extend
to prenatal life and are an important cause of early infantile cardiac failure.Mitochondrial dysfunction is a major cause of metabolic
disorders in adults and children and presents a wide vari-
ability of organ manifestations. Mitochondrial DNA
(mtDNA) mutations explain 10%–30% of these disorders,
the rest being caused by defects in nuclear-encoded mito-
chondrial proteins.1 The genetic causes of primary mito-
chondrial cardiomyopathies (CMPs) are, however, poorly
known, although CMP is an important manifestation
among children withmitochondrial disease.2–4 In addition
to mutations in the mitochondrial tRNA for isoleucine
(MT-TI [MIM 590045]),5 nuclear mutations in SCO2
(MIM 604272),6 TAZ (MIM 300394),7 and TMEM70
(MIM 612418)8 have previously been identified in disor-
ders with early-onset mitochondrial CMP. The prognosis
of children with mitochondrial CMP is particularly poor,
with an 18% survival rate at 16 years of age, whereas
patients with neuromuscular symptoms but without
CMP have a 95% survival rate at the same age.3 Infantile
CMPs typically lead to early death. In the present study,
we set out to identify the genetic causes of mitochondrial
CMPs by using whole-exome sequencing.1Research Programs Unit, Molecular Neurology, Biomedicum-Helsinki, Univer
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The AmeAll patient samples were taken according to the Declara-
tion of Helsinki, with informed consent given prior to
sample collection. The project was approved by the review
board of the Helsinki University Central Hospital. Our
index patientwas a girl with infantilemitochondrial hyper-
trophicCMP (patient II-1, family1; Figure1A). Shewasborn
healthy but somewhat small (2945 g) to nonconsanguine-
ous parents after an uneventful pregnancy. At 3.5 months
she was admitted to the hospital because of poor feeding,
failure to thrive, delayed motor development, and severe
generalized muscle weakness. She was alert, had normal
eye movements without ptosis, but had hypoactive deep
tendon reflexes. Ophthalmological examination did not
reveal retinopathy or optic atrophy. Urinary organic
acids showed marginal increase in ethylmalonic acid.
Chest X-ray showed cardiomegaly, and cardiac ultrasound
showed a severely hypertrophic left ventricle with
decreased contractility (ejection fraction 40%). Brain
magnetic resonance imaging was normal, but electroen-
cephalogram showed mild background abnormality with
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Figure 1. The Mitochondrial Cardiomyopathy
Patients and Their Families
(A) Pedigrees of families 1 and 2.
(B) Cytochrome c oxidase (COX) activity (shown in
brown) of heart and skeletal muscle of patients 1
(II-1, family 1) and 2 (II-6, family 2). Simultaneous
histochemical analysis for COX and succinate dehy-
drogenase (SDH, shown in blue) activities (Cox/Sdh)
on frozen cryostat sections revealed mitochondrial
COX deficiency with mitochondrial proliferation.
(C) Blue native electrophoresis analyses of mito-
chondrial respiratory chain complexes in the heart,
brain, and liver of patient 1 (P1), compared to
control samples (c). Ten micrograms of sample
protein was loaded onto a gel. For protein detection,
monoclonal antibodies (Mitosciences) against the
39 kDa subunit of Complex I (CI), the subunits
core 2 or Rieske of Complex III (CIII), the cox1p
and cox4 subunits of Complex IV (CIV), and the
70 kDa-Ip subunit of Complex II (CII) were used.had lactic acidosis (up to 7 U/l; normal < 2.3 mmol/l)
but normal plasma creatine kinase (108 U/l; normal
50–270 U/l) and alanine aminotransferase (36 U/l; normal
< 50 U/l). At 4 months of age, her muscle sample showed
scattered cytochrome c oxidase (COX,mitochondrial respi-
ratory chain complex IV)-deficient muscle fibers, which
suggested generalized muscle dysfunction and was consid-
ered a contraindication for heart transplantation. Other
organs, including the retina and liver, showed no signs of636 The American Journal of Human Genetics 88, 635–642, May 13, 2011disease. Her disorder progressed despite inten-
sive medication for heart failure and supple-
mentation of carnitine, CoQ, riboflavin, or
medium chain triglycerides. She died at the
age of 10 months of cardiac insufficiency.
Autopsy showed a severely enlarged, dilated,
and hypertrophic heart, which compressed
the lung and caused mild pulmonary hypo-
plasia. Light microscopic examination of
cardiac muscle showed scattered lymphocyte
infiltration, ischemic myocytes, perinuclear
vacuolization, and fat accumulation, consis-
tent with histiocytoid CMP. Postmortem, 80%
of cardiomyocytes and 60% of skeletal muscle
fibers were COX deficient and succinate
dehydrogenase (SDH) positive (Figure 1B). The
cardiac COX deficiency manifested in the
whole organ and was particularly prominent
in the papillary muscles and underneath the
endocardium. The liver histology showed
mild fat infiltration. The skeletal muscle
showed fat accumulation and moderate fiber
size variation, including small atrophic and
few enlarged, mostly type 1 fibers (Figure 1B).
Neuropathologic findings were mild and
unspecific, but some vacuolization of the
neuropil combined with capillary congestion
was detected, especially in the pontine
tegmentum. Blue native electrophoresis (BN-PAGE) of the mitochondrial respiratory chain (RC)
complexes9 revealed a near-total lack of COX and complex
I (CI) in the heart, severe COX deficiency and reduction of
CI in the brain, and partial complex III (CIII) deficiency
in both tissues, whereas all complexes were unaffected
in the liver (Figure 1C). For the exclusion of pathogenic
mtDNA mutations, total DNA from frozen muscle
tissue was extracted by standard methods, and mtDNA
was amplified by PCR in two fragments, followed by DNA
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Figure 2. Schematic Representation of the Exome Data Analysis
and Data Filtering
(1) The known dbSNP130 variants were excluded assuming the
pathogenic variant to be too rare to (yet) exist in the database.
(2) Nongenic variants were excluded. (3) Homozygous changes
were selected: autosomal infantile-onset mitochondrial disorders
are generally recessively inherited and homozygosity of the path-
ogenic variant was considered possible as the patient originated
from Finland, a genetic isolate. (4) The consequence of the remain-
ing variants was assessed by SIFT Genome tool (5) Genes encoding
proteins with a mitochondrial function were predicted by Mito-
Prot and TargetP.sequencingwith several internal primers (Table S2 available
online).
To identify the causative nuclear gene mutation, we
sequenced the exome of patient II-1 in family 1. The
patient’s genomic DNA was isolated from cultured fibro-
blasts, and exome targets were enriched with the SureSe-
lect Human All Exon Kit (Agilent Technologies), and
sequenced with the use of the Illumina Genome
Analyzer-IIx platform. The 2382 bp paired-end sequence
reads were aligned to the hg19 reference genome with
the Burrows-Wheeler Alignment tool.10 The Pileup utility
from the SAMTOOLS package was used for variant
calling.11 The procedure yielded 5.3 Gb of mappable
sequence, of which 3.1 Gb (58%) was mapped on SureSe-
lect exome coordinates, resulting in 833 mean coverage
for target bases. From the 65,849 identified SNPs, the path-
ogenic variant was identified by the following scheme: (1)
The known dbSNP130 variants were excluded, under the
assumption that the pathogenic variant was too rare to
yet exist in the database. (2) Nongenic variants were
excluded. (3) Homozygous changes were selected, because
autosomal infantile-onset mitochondrial disorders are
generally recessively inherited and homozygosity of the
pathogenic variant was considered possible given that
the patient originated from Finland, a genetic isolate. (4)
The consequence of the remaining variants was assessed
by the SIFT Genome tool.12 (5) Genes encoding proteins
with a mitochondrial function were predicted by MitoProt
and TargetP (Figure 2). The serial filtering of the data led us
to identify a single change affecting a putative mito-
chondrial protein: a homozygous missense mutation
(c.1774C>T [p.Arg592Trp], RefSeq accession number
NM_020745.2) on chromosome 6 in exon 13 of AARS2
(MIM 612035), encoding a putative mitochondrial
alanyl-tRNA synthetase (mtAlaRS) (Figure 3A). We inde-
pendently carried out homozygosity mapping on the
patient’s DNA with the Infinium Human660W SNP Array
(Illumina) and, using the runs of homozygosity screen
option in PLINK,13 identified the largest continuous
homozygosity (3.3 Mb, 716 consecutive SNPs) on the
region of chromosome 6 that contained AARS2. Both
parents were heterozygous for the mutation.
AARS2 consists of 22 exons and encodes a protein of 985
amino acids (Figure 3C). We sequenced AARS2 in 14
patients with primary mitochondrial CMP (age at onset:
1 day–15 yrs) from our pediatric patient material (~150
patients), all of whom have a suspected mitochondrial
RC deficiency but no molecular diagnosis. The exons of
AARS2 were sequenced from total DNA with primers
designed to flank introns and untranslated regions (Table
S3). We identified the c.1774C>T (p.Arg592Trp) mutation
in a female, who was compound heterozygous for another
missense mutation in exon 3, c.464T>G (p.Leu155Arg)
(patient II-6, family 2; Figure 1A). She was from a family
of healthy, nonconsanguineous parents with four healthy
children and was born at week 40þ6, weighing 3220 g.
Toward the end of the pregnancy term, cardiac recordingsThe Ameshowed extrasystolia every ten beats, but otherwise the
pregnancy was uneventful. Her condition was poor imme-
diately after birth; her Apgar score was 5/5. She required
mechanical ventilation, but oxygen saturation was only
70%. Postnatal ultrasound showed a large hypertrophic
heart with poor myocardial contractility, and she devel-
oped severe metabolic acidosis (lactacidosis; base excess
25). CNS affision was suspected because of staring gaze
and periodical stiffness. EEG showed decreased basic
activity and suspicion of bursts, with asymmetry between
the hemispheres. Vitamin supplementations or carnitine
had no effect on the progressive disease. She died at post-
natal day 3. Autopsy showed an enlarged, hypertrophic
heart and pulmonary hypoplasia but no pathological
changes in the brain and liver, as well as severe COX defi-
ciency in the heart and skeletal muscle (Figure 1B). Table S1
shows RC activity measurements,14 consistent with
CIþCIV deficiency in the heart, brain, and skeletal muscle
but not in the liver. Her brother (patient II-3, family 2;
Figure 1A) had died in utero at pregnancy week 40þ1,
with the autopsy showing hypertrophic heart with cardio-
myopathic histology and pulmonary hypoplasia. The
parents of the patients were heterozygous carriers of the
mutations. Neither mutation was found in 400 Finnish
control chromosomes, which were screened by solid-phase
minisequencing15 with mutation-specific detection
primers (Table S2). Other CMP patients in our cohort did
not have AARS2 mutations.
Our multiple sequence alignment of the putative
mtAlaRSs with known bacterial alanyl-tRNA synthetases,
obtained via the PROMALS3D server, showed that the
human enzyme has 31% identity and 45% similarityrican Journal of Human Genetics 88, 635–642, May 13, 2011 637
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Figure 3. AARS2 and Mutations
(A) AARS2 mutation sequences in patients 1 (II-1, family 1) and 2 (II-6, family 2).
(B) Cross-species protein conservation of mtAlaRS, flanking the altered amino acids p.Leu155Arg and p.Arg592Trp inmammals. The cor-
responding gene has not been fully characterized in other vertebrate species.
(C) Schematic representation of AARS2. Boxes represent exons 1–22. Twomain functional domains, the aminoacylation (pink) and edit-
ing (green) domains, are indicated. M denotes the mitochondrial targeting signal. The p.Leu155Arg mutation is located in the amino-
acylation domain, p.Arg592Trp in the editing domain.
(D) The AARS2-GFP fusion protein (green) colocalizes with Mitotracker Red (Invitrogen), indicating mitochondrial localization for
mtAlaRS in HEK293T cells (overlay in yellow). The cells were examined and imaged with an Olympus IX8 fluorescence microscope.with E. coli AlaRS, suggesting it to be the enzyme respon-
sible for the charging of tRNAAla with alanine during mito-
chondrial translation. MitoProt and TargetP prediction
algorithms suggested a likely N-terminal mitochondrial
targeting signal for mtAlaRS. We cloned the full coding-
region cDNA of AARS2 (excluding the stop codon) into
pEGFP-N1 (Clontech) and used the Neon transfection
system (Invitrogen) to express the AARS2-GFP fusion
protein in HEK293T cells according to the manufacturer’s
protocol. As a result, AARS2-GFP fusion protein was effi-
ciently targeted to mitochondria in the cells (Figure 3D).
The Leu155 and Arg592 residues are highly conserved in
mammalian mtAlaRSs, except for the ortholog of Arg592
in mouse (Figure 3B). To assess the consequences of
p.Leu155Arg and p.Arg592Trp substitutions on the
enzyme function, we generated a homology model for
mtAlaRS by using SWISS-Model Server (Figure 4A). For
modeling of the fragment encompassing residues 36–638 The American Journal of Human Genetics 88, 635–642, May 13,491, the structure of the corresponding domain from the
homologous E. coli AlaRS16 (residues 2–441) (PDB 3HXU,
chain A) sharing 37.6% sequence identity was used. The
domain of P. horikoshii AlaRS17 encompassing 540–752
residues (PDB 2ZZF, chain A) was used as a template for
modeling of the human mtAlaRS aa 556–784 fragment.
Sequence identity between these fragments is 30.2%. A
structure model of the mtAlaRS molecule without 233
C-terminal residues was attained by superimposition
of the obtained domains with the structure of the
P. horikoshii AlaRs17 (PDB 2ZZF) (Figure 4A). Modeling
of the tRNAThr (PDB 1QF6) into the editing domain of
the modeled mtAlaRS was performed as previously
described.17,18 Superimposition of the structures, docking
of the tRNA, and structure analysis was performed with
VMD software19 and Discovery Studio 2.5.5 (Accelrys).
Sequence analysis and the attained structure predict that
human mtAlaRS, similar to its bacterial orthologs, has an2011
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(A) The location of Leu155 within the ami-
noacylation domain (pink) and of Arg592
within the editing domain (green). The
strand-loop-strand motif (aa 764–783) in
the editing domain is shown in yellow.
(B) Hydrophobic architectural residues
surrounding the catalytic aminoacylation
site. Carbon atoms of the catalytic residues
involved in amino acid binding and ami-
noacyl adenylate formation are shown in
magenta.
(C) Conserved positively charged residues,
predicted to be involved in the recognition
and binding of tRNA (yellow) in the edit-
ing domain of human mtAlaRS.
(D) Comparative analysis of the predicted
secondary structures of human cyto-
plasmic and mitochondrial tRNAAla re-
vealed that the identity base pair of the
latter is likely to be G5:U64, implying
a structurally unique tRNA recognition
site in the human mtAlaRS.N-terminal aminoacylation domain (aa 36–481) for
charging tRNAAla, an editing domain (aa 484–782) for de-
acylation, if tRNAAla is mischarged with serine or
glycine,20,21 and a structural C-terminal domain (aa 883–
985) linking the aminoacylation and editing functions.22
The residue Leu155 was found to be located in the amino-
acylation domain and Arg592 within the editing domain
(Figure 3C). Our model shows that Leu155 is one of the
architectural residues surrounding the catalytic aminoacy-
lation site (Figure 4B). Substitution of Leu155 for positively
charged arginine is predicted to severely affect the amino-
acyl adenylate formation by altering the position of the
neighboring Trp241 and consequently Asn242, the analog
of which was shown in bacterial AlaRSs (Asn194 in
A. aeolicus and Asn212 in E.coli) to be one of the key cata-
lytic residues.16,23
Arg592 is predicted to be located in the editing domain
of mtAlaRS at a distance of 21.15 A˚ from the editing site
at the same plane with an anti-parallel four-stranded
b sheet of the domain. The strand-loop-strand motif of
this b sheet formed by aa 64–783 (shown in yellow in Fig-The American Journal of Humanure 4A) corresponds to the tRNAAla
recognition motif of E. coli AlaRS
(aa 680–699).17,18,24 The cytosolic
alanyl-tRNA synthetases identify
cytoplasmic tRNAs on the basis of
a single conserved wobble G3:U70
base pair in the acceptor stem.25
However, in fruit fly mitochondrial
tRNAAla, the position of the critical
G:U base pair is shifted to 2:71.26
Using the DINAMelt server, com-
parative analysis of the predicted
secondary structures of human cyto-
plasmic and mitochondrial tRNAAla
(GenBank NC_012920.1, comple-ment 5587–5655 nt) revealed that the identity base pair
of the latter is likely to be G5:U64, which implies a structur-
ally unique tRNA recognition site in the human mtAlaRS
(Figure 4D). Analysis of the AlaRSs sequence alignment
and the mtAlaRS structural model revealed that the
surface-exposed basic amino acid residues Arg592,
His656, and Arg769 are unique for the mitochondrial
enzyme (Figure S1). Docking of bacterial tRNAThr as
a template (tRNAAla has not been resolved) into the struc-
tural model showed that these residues together with
invariant Arg663 and Arg777 form a positively charged
patch that contacts the acceptor stem of tRNA from the
minor groove in the same manner proposed for bacterial
AlaRSs17,18,24 (Figure 4C). Given that Arg592 approaches
the tRNA at the level of the G5:U64 base pair, we propose
that it is involved in specific recognition and/or binding of
mischarged mitochondrial tRNAAla in the editing domain.
Therefore, p.Arg592Trp substitution likely impairs the edit-
ing activity of mtAlaRS, leading to increased mistransla-
tion of alanine by serine or glycine. Homozygosity for
the editing domain mutation was compatible with lifeGenetics 88, 635–642, May 13, 2011 639
for several months after birth, whereas aminoacylation
domain defect in association with the editing dysfunction
led to perinatal death.
Both AARS2 mutations caused a near-total deficiency of
RC complexes in the heart of the patients, leading to
primary manifestation as a CMP, and caused partial defi-
ciency of RC complexes in the skeletal muscle and brain
but not in the liver. The severe CMP led to early death of
the patients, but the reduction of RC complexes in the
other tissues indicated multiorgan manifestation. Next,
we investigated the effects of the mutations on RC by
BN-PAGE (data not shown) and on mitochondrial transla-
tion by translation assays in fibroblasts and in myoblasts
or myotubes from the patients. For translation assays,
primary cells were pulse-labeled for mitochondrial transla-
tion products with 35S methionine in the presence of emi-
tine, a cytosolic translation inhibitor.14 No defects were,
however, observed in any cell types through the use of stan-
dard culture conditions. If galactose is replaced by glucose
as the carbon source for cultured cells, the slowmetabolism
of galactose to glucose-1-phosphate renders the cells depen-
dent on glutamine and pyruvate for ATP production.27
Therefore, galactose promotes a metabolic shift from
glycolysis to oxidative energy metabolism, and cells with
a dysfunctional RC fail to grow.28 However, even in galac-
tose culture, the mitochondrial translation and cell growth
of the patient cells was similar to that of control cells
(Figure S2A). Proofreading-deficient AlaRSs have been
shown to allow misincorporation of serine, with profound
functional consequences:16 cytoplasmic AlaRS defect has
been shown to lead to accumulation of misfolded proteins
and sensitivity to serine.29 However, we found no defects in
mitochondrial translation, even when the proofreading-
deficient mtAlaRS patient cells were grown in galactose
medium with 5 mM L-Serine (Sigma-Aldrich) for 24 hr
(Figure S2A). These results demonstrate that the manifesta-
tion of AARS2mutations is restricted to certain postmitotic
tissues, the mechanism of which is presently unclear.
We found the uncharged mitochondrial tRNA alanine
(MT-TA) levels to be unaltered in the heart or muscle of
patient 1 (II-1, family 1; Figure S2B). For the RNA blot, total
RNA from heart and skeletal muscle postmortem tissues of
the patient and of an age-matched control was extracted
with Trizol reagent (Invitrogen) in a FastPrep 24 Lysing
Matrix D tube (MP Biomedicals). Ten micrograms of RNA
was run on a 15% 7M Urea polyacrylamide gel and blotted
onto a positively charged nylon membrane (Amersham
Hybond-XL nylon). The RNA was hybridized with g-[32P]
ATP-labeled oligonucleotide probes against:MT-TA 50-ACT
GAACGCAAATCAGCCAC-30, and U6 small nuclear 1
(RNU6-1) RNA 50-GGAACGCTTCACGAATTTGC-30 was
used as a loading control.
We hypothesized that the tissue-specificmanifestation of
the CMP could be explained by variable amino acid concen-
trations in different tissues, especially those of glycine and
serine, which in the case of proofreading-deficient mtAlaRS
could influence the misincorporation rate of serine and640 The American Journal of Human Genetics 88, 635–642, May 13,glycine in RC complexes. Therefore, we also quantified free
amino acid levels in patient tissues bymetabolomic analysis
using comprehensive two-dimensional gas chromatog-
raphy, combined with time-of-flight mass spectrometry.30
The available postmortem samples for the quantification
of amino acids were from the heart, muscle, and liver
of patient 1 (II-1, family 1), the heart and muscle of
a 10-month-old child with a nonmitochondrial dilated
familial CMP, and the heart and liver of a 10-year-old girl
with an isolated CI deficiency and mitochondrial encepha-
lopathy. The tissue sampleswere homogenizedwithCovaris
cryohomogenizer and extracted with methanol after the
addition of internal standard mixture (C17:0, valine-d and
succinic acid-d4). After centrifugation, the supernatant was
evaporated to dryness and the samples were trimethylsily-
lated (25 ml MOX, 45C, 60 min; 25 ml MSTFA, 45C,
60 min). For the analysis, a Leco Pegasus 4D GC 3
GC-TOFMS instrument (Leco, St. Joseph,MI,USA) equipped
with a cryogenic modulator was used. For the quantitative
analysis of amino acids, calibration curves were constructed
at the concentration range at which the method was linear
(20–1500 ng) and repeatable for all of the studied amino
acids, with relative standard deviation below 10%. We did
not detect considerable differences in glycine or serine
concentrations between tissues, but we did find increased
levels of alanine in the patient heart and muscle, but not
in the liver (Figure 5). Alanine can be secreted from RC-defi-
cient skeletal muscle for gluconeogenesis in the liver, and
therefore the high alanine may be an unspecific response
to RCdefect. However, it could also be a compensatory feed-
backmechanism occurring upon deficient tRNAAla aminoa-
cylation, which remains to be studied.
Mutations in the mitochondrial aminoacyl-tRNA syn-
thetases are emerging as an important cause of disease,
but fascinatingly, they underlie a spectrum of different
phenotypes. DARS2 (MIM 610956) and RARS2 (MIM
611524) mutations have been shown to affect the CNS,
causing childhood- or juvenile-onset leukoencephalop-
athy with brainstem and spinal cord involvement and
lactate elevation31 and infantile encephalopathy and pon-
tocerebellar hypoplasia,32 respectively. A YARS2 (MIM
610957) mutation has been shown to affect the skeletal
muscle and cause sideroblastic anemia,33 whereas very
recently, SARS2 mutations were reported to lead to hyper-
uricemia, pulmonary hypertension, renal failure, and
alkalosis.34 Our findings add mutations in another mito-
chondrial aminoacyl-tRNA synthetase as a cause of disease
and indicate that these defects can underlie severe CMPs.
We conclude that mitochondrial aminoacyl-tRNA synthe-
tase defects mimic mitochondrial tRNA mutations, having
a wide range of tissue-specific manifestations. However,
defects in a mitochondrial aminoacyl-tRNA synthetase
and its corresponding mitochondrial tRNA do not neces-
sarily lead to similar disease phenotypes: for example,
MT-TA mutations have been found to cause adult-onset
ophthalmoplegia and dysphagia or pure myopathy (MIM
590000),35–37 not CMP.2011
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Figure 5. Metabolomic Analysis: Postmortem Heart and
Skeletal Muscle of Patient Shows Increased Alanine Levels
Patient 1 (II-1, family 1) heart, muscle, and liver samples were
compared to those of an age-matched patient with nonmitochon-
drial dilated CMP (heart and skeletal muscle) and those of
a 10-year-old patient with mitochondrial encephalopathy (heart
and liver).Childhood CMPs often remain without molecular diag-
nosis because of small familymaterials, tissue-specificmani-
festation, and lackof a cell culture phenotype,whichhas left
few tools for identification of gene defects by the means of
linkage analysis or functional complementation. We
demonstrate here that whole-exome sequencing is a power-
ful tool for use in finding a molecular diagnosis for such
patients, providing clues that allow us to understand patho-
genesis and a means of providing genetic counseling to the
families. Our results show that the spectrum of mitochon-
drialCMPsextends toperinatal-manifesting lethaldisorders.The AmeSupplemental Data
Supplemental Data include two figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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